Value investor Guy Spier closed his Aquamarine fund in early 2026 after being diagnosed with glioblastoma [1].
The decision marks a significant pivot for a prominent figure in the value investing community. By returning capital to investors, Spier is shifting his priorities from the pursuit of financial returns toward the management of his time and the creation of a lasting legacy.
Spier, known as a disciple of Warren Buffett, launched the Aquamarine fund in 1997 [2]. He gained widespread attention in 2007 when he paid just over $650,000 [3] at a charity auction for the opportunity to have lunch with Buffett. That meeting helped solidify his approach to investment and professional ethics.
Following the 2026 diagnosis of glioblastoma [4], a rare and aggressive form of cancer, Spier decided to wind down his professional fund operations. He returned the remaining capital to his investors in early 2026 [5].
In an interview with CNBC, Spier said the illness forced him to re-evaluate his views on wealth and time. He is now focusing his efforts on impact, specifically regarding rare-disease research.
This transition represents a total departure from the metrics of success that governed his career for nearly three decades. While the Aquamarine fund was built on the principles of long-term value, Spier is now applying those principles to his own life expectancy and philanthropic goals.
“The illness made him re-evaluate wealth, time, and legacy.”
Spier's decision to liquidate a fund held since 1997 underscores a broader trend of high-net-worth individuals pivoting toward 'impact philanthropy' when facing mortality. By prioritizing rare-disease research over fund management, Spier is transitioning his financial capital into social capital, reflecting a shift in value from capital accumulation to systemic medical advancement.
